Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule incoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.

Abstract: DNA comprising a regulatory gene for clavulanic acid biosynthesis. DNA is no greater than 7 kb in length and has the configuration of restriction sites shown in FIG. 1 or a fragment thereof. Use of DNA in a method for producing clavulanic acid in a host.

Abstract: The invention relates to heterocyclic compounds of formula (I) or a salt thereof wherein R1 is hydrogen or C1-6 alkyl; R2, R3 and R4 groups are independently hydrogen, halogen or C1-6 alkyl optionally substituted by one or more fluorine atoms, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

Abstract: Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.

Abstract: Compounds of formula (I) wherein: R1 represents a substituent selected from: a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-4alkyl, C1-4alkoxy, arylC1-4alkoxy, C1-4alkylthio, C1-4alkoxyC1-4alkyl, C3-6cycloalkylC1-4alkoxy, C1-4alkanoyl, C1-4alkoxycarbonyl, C1-4alkylsulfonyl, C1-4alkylsulfonyloxy, C1-4alkylsulfonylC1-4alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-4alkyl, C1-4alkylsulfonamido, C1-4alkylamido, C1-4alkylsulfonamidoC1-4alkyl, C1-4alkylamidoC1-4alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-4alkyl, arylcarboxamidoC1-4alkyl, aroyl, aroylC1-4alkyl, or arylC1-4alkanoyl group; a group R5OCO(CH2)p, R5(CON(R6)(CH2)p, R5R6NCO(CH2)p or R5R6NSO2(CH2)p where each of R5 and R6 independently represents a hydrogen atom or a C1-4alkyl group or R5R6 forms part of a C3-6azacycloalkane or C3-6(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar3—Z, wherein Ar3 repre

Abstract: A tablet formulation which comprises a core containing a pharmaceutically active material containing amoxycillin and clavulanate, coated with a release retarding coating, surrounded by a casing layer which includes a second pharmaceutically active material containing amoxycillin and clavulanate.

Abstract: This invention provides 29-desmethylrapamycin of Formula I: and a pharmaceutical composition thereof.

Abstract: A controlled release formulation of an acetonitrile compound and its use in the treatment and/or prophylaxis of certain disorders.

Abstract: Human histamine H3 gene variant-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human histamine H3 gene variant-2 polypeptides and polynucleotides in diagnostic assays.

Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of Compound (I) and insulin to a mammal in need thereof.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, and the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof:

Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent, to a mammal in need thereof; and composition for use in such method.

Abstract: A process for the preparation of a 4-aryl-3-oxymethyl-piperidine of structure (1) 1

Abstract: A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range of from >126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitizer, to a mammal in need thereof.

Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the prevention of atheroma progression and the regression of atheroma.

Abstract: Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterized in that it:

Abstract: A device for separating polymeric beads from a suspension of such beads comprising a flow cell through which the suspension of beads flows, and a radiation source which the stream of beads crosses. A detector detects the presence of a bead in the flow cell and control means directs the bead to a bead outlet channel.

Abstract: Novel carboxamide derivatives having CNS activity, processes for their preparation and their use as medicaments

Abstract: The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for the treatment of angina.

Abstract: Paroxetine hydrochloride is obtained in a free-flowing and easily soluble form (suitable for preparing solid formulations or aqueous solutions, suitable for parenteral use) by spray-drying solutions of paroxetine hydrochloride hemihydrate or other anhydrate/hydrate/solvate/amorphous forms.